Cassava Sciences Inc (SAVA)

[polarbear77]

I’ll take the actual positive and consistent trial and real world results (just a sample of which excerpted below) over pompous self-righteousness and negative bias on your part, every day of the week.



https://www.anavex.com/proof-of-concept-controlled-phase-2-clinical-trial-data-evaluating-anavex2-73-blarcamesine-in-parkinsons-disease-dementia-presented-at-ctad-2020-conference/

Statistically significant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time (p = 0.039) and Digital Vigilance (p = 0.008)

Statistically significant dose-dependent improvements in Episodic Memory (p = 0.003)

ANAVEX®2-73 (blarcamesine) prevented the on-going cognitive decline in treated patients compared to placebo

Late breaking abstract of cognitive outcome measures relevant to Alzheimer’s disease selected for oral presentation at CTAD







https://www.globenewswire.com/news-release/2019/12/04/1956062/0/en/Anavex-Life-Sciences-Presents-ANAVEX-2-73-blarcamesine-Data-at-12th-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-2019-Conference.html



“Propensity score matching (PSM) was applied using Linear Mixed Effects (LME) models including descriptors of age, sex, SIGMAR1 p.Q2P carrier status, APOE4 allele and MMSE at baseline to select patients with similar baseline characteristics and any confounding factors between AD patients in the Phase 2a ANAVEX®2-73 (blarcamesine) cohort and AD patients from the ADNI control cohort.

Change in MMSE score from baseline at week 104 of matched cohorts was assessed. It showed that ANAVEX®2-73 (blarcamesine) high dose cohort had a significantly lower MMSE decline (-1.1) compared to the ADNI control cohort (-4.4) at week 104 (p < 0.01).“









https://www.arianapharma.com/2018/10/arianas-ai-demonstrate-clinical-efficacy-of-anavex2-73-for-alzheimers-patient-ctad-2018/



Using Ariana’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, the analysis of the longitudinal 3-year(148-week) data showed that patient cohort with the higher concentration of ANAVEX®2-73 maintains Activities of Daily Living Score (ADCS-ADL) and display a reduced cognitive decline (MMSE) when compared to the lower concentration cohort.






https://www.anavex.com/anavex-life-sciences-announces-anavex2-73-blarcamesine-meets-primary-and-secondary-endpoints-in-placebo-controlled-u-s-phase-2-clinical-trial-for-the-treatment-of-adult-patients-with-rett-syn/




Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome



Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I

Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms and correlated with changes in biomarker (glutamate) of disease pathology

Key milestone met to advance regulatory approval pathway for adult patients with Rett syndrome





UC Davis Rett Trial Comments:

Bonus footage for you of the 1st hand accounts of and comments yesterday from the research doctor from UC Davis that has dedicated her career to these CNS patients and Rett Syndrome patients and associated research. Reference time stamps 38:20 and 1 hr 15 minutes in particular pertaining to 2-73 (blarcamesine):